EvolveImmune Therapeutics

Executive Summary

EvolveImmune Therapeutics is a private biotechnology company pioneering a novel class of cancer immunotherapies through its proprietary EVOLVE platform, which generates trispecific T-cell engagers with integrated CD2 costimulation. This approach aims to overcome resistance mechanisms that limit the efficacy of current T-cell engagers and checkpoint inhibitors. The company's lead candidate, EVOLVE104, is positioned to enter clinical development, targeting solid tumors. EvolveImmune's strategy leverages the unique ability of CD2 costimulation to enhance T-cell activation and persistence while reducing exhaustion. As a privately held firm founded in 2019 and headquartered in Branford, Connecticut, the company has not disclosed funding amounts or valuation but represents an emerging player in the competitive immuno-oncology space. Its success hinges on demonstrating clinical proof-of-concept and differentiating its platform from other multispecific engagers.

Upcoming Catalysts (preview)

• H1 2026Initiation of Phase 1 Trial for EVOLVE10460% success
• Q2 2026Presentation of Preclinical Data at Major Oncology Conference80% success
• H2 2026Announcement of Series A Financing or Strategic Partnership50% success